SRx Health Solutions (SRXH) Q2 2024 earnings summary

Executive summary

• Net income rose 190% year-over-year to $2.7 million in Q2 2024, with EPS up 170% to $2.98, driven by a $3.6 million gain on extinguishment of debt and strategic exits from unprofitable channels.

• Achieved a 95% average fill rate in Q2 2024, up 20 percentage points year-over-year.

• Adjusted EBITDA improved 98% year-over-year to a $30,000 loss, reflecting operational improvements.

• Strategic pivots included shifting marketing investments to major online platforms, launching Halo Elevate on Chewy, and migrating D2C customers to more profitable digital channels.

• Leadership team with deep experience in consumer packaged goods and pet industry turnarounds.

Financial highlights

• Q2 2024 net sales were $8.5 million, up 8% sequentially but down 19% year-over-year; H1 2024 net sales were $16.5 million, down from $19.8 million year-over-year.

• Gross margin in Q2 2024 reached 38%, up 400 basis points year-over-year; Q2 gross profit was $3.3 million.

• Operating loss improved 72% year-over-year in Q2; adjusted EBITDA improved 98% to a $30,000 loss.

• Free cash flow for Q2 was approximately $100,000; cash and cash equivalents as of June 30, 2024, were $3.3 million.

• Debt reduced by $5.5 million; plan to retire another ~$5 million in accounts payable at a discount in Q3.

Outlook and guidance

• Management expects continued profitability improvements, adjusted EBITDA margin expansion, and growth for the Halo brand, especially via Chewy and Amazon.

• Strategic pivots and operational discipline are expected to drive further growth and margin improvement.

• Plans to accelerate growth through omnichannel expansion, international partnerships, and targeted M&A.

• Focus on operational efficiency, reducing OpEx, and optimizing overhead to scale profitably.

• Ongoing efforts to achieve operating profitability and address going concern risks.